University of Western Australia
Crawley, Perth, 6009, Australia
NCT Number: NCT03520452
This study evaluates effects of different doses of chlorogenic acids on vascular health.
Looking for future studies?
Notify Me45 year–65 year
All sexes
Interventional
Not applicable
Crawley, Perth, 6009, Australia
It has been suggested that consumption of food rich in chlorogenic acids can help to improve vascular health, measured by flow mediated dilation.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Reconstituted in water and given to subjects
Placebo
Time frame: 24 hours
The primary outcome will be the average change from baseline (i.e. predose) in the %Flow Mediated Dilation
Time frame: 24 hours
link for endothelial function improvement
Time frame: 24 hours
Area Under Curve of the concentration/time curve
Time frame: 24 hours
link for endothelial function improvement
Time frame: 24 hours
link for endothelial function improvement
Time frame: 24 hours
Blood concentrations in plasma.
Time frame: from first dose till last visit
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Société des Produits Nestlé (SPN)
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03778307
Endothelial Dysfunction, Mental Disorders
Los Angeles, California, United States
View Trial DetailsNCT06472791
Endothelial Dysfunction
Portland, Oregon, United States
View Trial DetailsNCT07569744
Diabetes Mellitus, Diabetes Mellitus, Type 2
Palembang, South Sumatera, Indonesia
View Trial DetailsNCT05107869
Cardiovascular Diseases, Endothelial Dysfunction
Wauwatosa, Wisconsin, United States
View Trial Details